8-K: MetaVia Unveils Strong Phase 1 Obesity Data, Advances MASH Drug

MetaVia Inc. announced positive Phase 1 results for its obesity drug DA-1726 and met the primary endpoint in its Phase 2a trial for MASH treatment Vanoglipel, highlighting significant progress in its cardiometabolic pipeline.

Summary

• MetaVia Inc. released an updated corporate presentation detailing progress on its cardiometabolic pipeline, including DA-1726 for obesity and Vanoglipel (DA-1241) for MASH.
• DA-1726, a GLP1R/GCGR dual agonist, demonstrated compelling weight loss in its Phase 1 MAD study, with a mean reduction of 4.3% (max 6.3% or 15.4 lbs) at Day 26 for the 32 mg dose.
• The drug also showed significant reductions in fasted glucose (mean -5.3 mg/dL, max -18 mg/dL) and waist circumference (mean -4 cm, max -10 cm) at the 32 mg dose.
• DA-1726 exhibited a favorable safety and tolerability profile with no treatment-related discontinuations and mostly mild, transient GI-related adverse events.
• Vanoglipel (DA-1241), an orally available GPR119 agonist for MASH, met its Phase 2a primary efficacy endpoint, showing direct hepatic effects and statistically significant reductions in ALT levels across all active arms.
• Vanoglipel also demonstrated significant reductions in HbA1C and CAP scores compared to placebo, indicating positive effects on glucose control and liver fat.
• The company reported a cash balance of $14.3 million as of September 30, 2025, with no debt.
• Key upcoming milestones include additional Phase 1 SAD/MAD studies for DA-1726 in Q2/Q3 and Q4 2025, an FDA meeting for Vanoglipel in H1 2026, and Phase 2a initiation and interim data readout for DA-1726 in Q2 and H2 2026, respectively.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical data for both lead candidates, DA-1726 for obesity and Vanoglipel for MASH, meeting primary endpoints and showing competitive efficacy and safety profiles. The clear development roadmap and potential for best-in-class attributes are highly favorable. However, the relatively low cash balance for a clinical-stage biotech with multiple trials could necessitate future capital raises, which introduces some financial risk.

Positives

• DA-1726 showed strong weight loss, with a mean of 4.3% and a maximum of 6.3% (15.4 lbs) at Day 26 for the 32 mg dose.
• DA-1726 demonstrated significant reductions in fasted glucose (mean -5.3 mg/dL, max -18 mg/dL) and waist circumference (mean -4 cm, max -10 cm).
• DA-1726 had no treatment-related discontinuations in its Phase 1 MAD study, with mostly mild and transient GI-related adverse events.
• Vanoglipel (DA-1241) met its Phase 2a primary efficacy endpoint, showing statistically significant reductions in ALT levels.
• Vanoglipel also showed significant reductions in HbA1C and CAP scores, indicating improvements in glucose control and liver fat.
• The company has a clear pipeline with multiple near-term milestones aimed at increasing shareholder value.
• Cash balance of $14.3 million and no debt as of September 30, 2025.
• DA-1726 demonstrated superior weight loss efficacy, body fat mass reduction, and lean body mass relative preservation compared to Survodutide in preclinical HF-DIO mice studies.
• DA-1726 further improved hepatic steatosis, inflammation, and fibrosis compared to semaglutide in DIO-NASH mice.

Negatives

• The 100mg dose of Vanoglipel (DA-1241) did not show a statistically significant proportion of subjects with normalized ALT <30 IU/L at Week 16 compared to placebo (p=0.1402), unlike the 50mg dose (p=0.0487).
• The combination arm of Vanoglipel 100mg + Sitagliptin 100mg also did not show a statistically significant proportion of subjects with normalized ALT <30 IU/L at Week 16 compared to placebo (p=0.4576).
• One subject in the Vanoglipel 100mg + Sitagliptin 100mg arm discontinued due to a treatment-emergent adverse event (3.1%).
• The company's cash balance of $14.3 million, while debt-free, may be a concern given the extensive clinical trial pipeline and the high costs associated with drug development.

Risks

• Ability to execute commercial strategy.
• Sufficiency of existing cash on hand to fund operations.
• Timeline for regulatory submissions, steps, and potential regulatory approval of current and future product candidates.
• Ability to realize the benefits of the license agreement with Dong-A ST Co., Ltd., including the impact on future financial and operating results.
• Ability to integrate current and future product candidates into the business in a timely and cost-efficient manner.
• Cooperation of contract manufacturers, clinical study partners, and others involved in the development.
• Ability to initiate clinical trials on a timely basis and recruit subjects for clinical trials.
• Costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement.
• Changes in applicable laws or regulations.
• Effects of changes to the stock price on the terms of the license agreement and any future fundraising.
• Actual events or results may differ materially from forward-looking statements.

Future Outlook

MetaVia Inc. anticipates advancing its lead obesity candidate, DA-1726, through additional Phase 1 studies in Q2/Q3 and Q4 2025, with a Phase 2a IND amendment planned for Q1 2026, followed by Phase 2a initiation in Q2 2026 and interim data readout in H2 2026. For Vanoglipel, a meeting with the FDA is expected in H1 2026. The company is actively seeking a combination/licensing partner for Vanoglipel and aims to increase shareholder value through these near-term milestones.

Management Comments

• We are aiming to increase Shareholder Value through Multiple, Near-Term, Value Creating Milestones.
• DA-1726 has strong weight loss at 4 weeks, potentially best-in-class tolerability and compelling safety with potential pathway to not only obese otherwise healthy patients but also obese T2D and obese MASH patients.
• Vanoglipel (DA-1241) Phase 2a top-line data in subjects with presumed MASH met primary end point and showed direct hepatic effects.
• Will be actively searching for a combination/licensing partner for Vanoglipel.

Industry Context

The cardiometabolic disease market, particularly for obesity and MASH, is experiencing significant innovation and high-value transactions, as evidenced by recent multi-billion dollar deals for GLP-1, GIP, and amylin analog assets. MetaVia's dual agonist DA-1726 and GPR119 agonist Vanoglipel position the company within this competitive and rapidly evolving landscape, targeting large unmet medical needs. The strong early clinical data for DA-1726 and the positive Phase 2a results for Vanoglipel suggest MetaVia is developing potentially differentiated therapies in a highly attractive therapeutic area.

Comparison to Industry Standards

• DA-1726 (32mg dose, 4 weeks, no titration) showed 4.3% mean weight loss and 6.3% max weight loss, which is competitive with early-stage data from other GLP-1R/GCGR agonists like Pemvidutide (10.3% at 12 weeks, 1.8mg), Mazdutide (9.8% at 12 weeks, 9mg), and Survodutide (5.79% at 6 weeks, titration to 0.45mg).
• DA-1726 demonstrated lower rates of mild vomiting (50% at 32mg) and nausea (33% at 32mg) compared to Pemvidutide (72.8% vomiting, 91% nausea at 2.4mg, 12 weeks) and Mazdutide (37.5% vomiting, 62.5% nausea at 9mg, 12 weeks) in their respective Phase 1 studies, suggesting potentially best-in-class tolerability.
• Preclinical studies showed DA-1726 had superior weight loss efficacy, body fat mass reduction, and lean body mass preservation compared to Survodutide in HF-DIO mice.
• DA-1726 also improved hepatic steatosis, inflammation, and fibrosis more effectively than semaglutide in DIO-NASH mice.
• Vanoglipel's significant reduction in HbA1C and CAP scores in MASH patients is a positive indicator, as many MASH patients also have metabolic comorbidities like type 2 diabetes.

Related Party Transactions

• Dong-A ST Co., Ltd. holds 41% of common stock (9,995,679 shares).
• Dong-A Socio Holdings Co., Ltd. holds 39% of common stock (9,436,620 shares).
• The company has a license agreement with Dong-A ST Co., Ltd.

Stakeholder Impact

• Shareholders: Positive clinical data and a clear development pipeline could increase shareholder value. However, potential future dilution from capital raises or warrant exercises could impact per-share value.
• Patients (Obesity/MASH): The development of DA-1726 and Vanoglipel offers potential new therapeutic options for significant unmet medical needs.
• Investment Professionals: The strong early data provides compelling insights for investment decisions in the cardiometabolic space.
• Regulatory Authorities: The company's planned FDA meetings and IND amendments indicate active engagement with regulatory pathways.
• Dong-A ST Co., Ltd. and Dong-A Socio Holdings Co., Ltd.: As major shareholders and a licensing partner, they stand to benefit significantly from successful drug development and commercialization.

Next Steps

• Conduct ongoing 4+4-week 48 mg dose cohort for DA-1726 to find the non-titrated maximum tolerated dose.
• Perform Phase 1 Additional SAD/MAD Studies for DA-1726 in Q2/Q3 2025.
• Release Phase 1 Additional SAD/MAD data for DA-1726 in Q4 2025 to explore maximum tolerated dose.
• Meet with the FDA regarding Vanoglipel in H1 2026.
• Submit Phase 2a IND Amendment for DA-1726 in Q1 2026.
• Initiate Phase 2a for DA-1726 in Q2 2026.
• Release Phase 2a 12-week Interim Data Readout for DA-1726 in H2 2026.
• Actively seek a combination/licensing partner for Vanoglipel.
• Release other exploratory endpoints for Vanoglipel, including MRI-PDFF, at major medical conferences.

Key Dates

Recommendation

The filing presents exceptionally strong early-stage clinical data for DA-1726 in obesity, demonstrating competitive weight loss, glucose reduction, and a favorable safety profile, positioning it as a potential best-in-class GLP1R/GCGR dual agonist. Simultaneously, Vanoglipel has successfully met its primary endpoint in Phase 2a for MASH, showing significant hepatic and metabolic improvements. The company's pipeline is robust, targeting high-value markets with clear, near-term milestones. While the cash balance warrants monitoring for future funding needs, the compelling clinical efficacy and safety data, coupled with the strategic importance of these therapeutic areas, suggest a strong upside potential for investors. The current valuation likely does not fully reflect the potential of these assets.

Keywords

Obesity, MASH, Cardiometabolic diseases, GLP1R/GCGR dual agonist, DA-1726, Vanoglipel, DA-1241, GPR119 agonist, Phase 1 clinical trial, Phase 2a clinical trial, Weight loss, Fasted glucose, Waist circumference, ALT reduction, HbA1C, Liver fat, Biotech, Clinical stage, Drug development, SEC filing, NASDAQ: MTVA